We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

3 hedge funds and large institutions have $920K invested in VanEck Vectors Generic Drugs ETF in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

31% less capital invested

Capital invested by funds: $1.33M → $920K (-$410K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$53.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$452K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$860K -$452K -18,950 -34%
IA
2
IFP Advisors
Florida
$54K +$53.7K +2,250 New
TRCT
3
Tower Research Capital (TRC)
New York
$6K -$1.22K -51 -18%

GNRX Hedge Fund Activity: Q2 2016 in Review

3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q2 2016, worth a combined $920K — down 31% from $1.33M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new GNRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was IFP Advisors, opening a new position worth an estimated $53.7K. The largest seller was UBS Group, cutting an estimated $452K.

  • 3 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q2 2016, up from 2 in Q1 2016.
  • Funds reported $920K of VanEck Vectors Generic Drugs ETF stock for Q2 2016, down 31% quarter-over-quarter.
  • 1 fund opened new VanEck Vectors Generic Drugs ETF positions in Q2 2016 and 0 closed out, a net change of +1 holder.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q2 2016 was IFP Advisors, an estimated $53.7K added.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q2 2016 was UBS Group, an estimated $452K sold.

Based on aggregated 13F filings for Q2 2016.